KLB (JMT202 Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA769815MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q86Z14

Alternative Names

JMT202 research-grade biosimilar ;KLB antibody; Beta-klotho antibody; BKL antibody; BetaKlotho antibody; Klotho beta-like protein antibody

Species Reactivity

Human

Immunogen

Recombinant Human KLB protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Buffer

0.01M PBS，pH7.4

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

3-4 weeks
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Concentration

It differs from different batches. Please contact us to confirm it.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody JMT202, targeting KLB (Klotho Beta). KLB functions as an essential co-receptor for fibroblast growth factor 19 (FGF19) and FGF21, forming complexes with FGF receptors to mediate critical metabolic signaling pathways. The KLB-FGF21 axis plays a pivotal role in regulating glucose and lipid metabolism, energy homeostasis, and insulin sensitivity. Dysregulation of KLB expression and signaling has been implicated in metabolic disorders including type 2 diabetes, obesity, non-alcoholic fatty liver disease, and cardiovascular complications, making it an important target for metabolic disease research.

As a biosimilar to JMT202, this antibody provides researchers with a reliable tool for investigating KLB protein expression, localization, and function in various experimental systems. It supports studies examining metabolic signaling mechanisms, FGF21-mediated pathways, and the role of KLB in disease pathogenesis. This antibody is particularly valuable for researchers exploring novel therapeutic strategies targeting metabolic dysfunction and related disorders.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Contributes to the transcriptional repression of cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis. Probably inactive as a glycosidase. Increases the ability of FGFR1 and FGFR4 to bind FGF21.

Gene References into Functions

Knockdown of beta-Klotho produced the opposite effects. In conclusion, beta-Klotho inhibits EMT and plays a tumorsuppressive role in prostate cancer (PCa) , linking FGF/FGFR/beta-Klotho signaling to the regulation of PCa progression. PMID:29749458
crystal structures of free and ligand-bound beta-klotho extracellular regions that reveal the molecular mechanism that underlies the specificity of FGF21 towards beta-klotho and demonstrate how the FGFR is activated in a klotho-dependent manner PMID:29342135
the metabolic FGF21/KLB/FGFR1 pathway is involved in congenital hypogonadotropic hypogonadism (CHH) Genetic screening of 334 CHH patients identified seven heterozygous loss-of-function KLB mutations in 13 patients (4%). Most patients with KLB mutations (9/13) exhibited metabolic defects. PMID:28754744
We conducted a genome-wide association meta-analysis and replication study among >105,000 individuals of European ancestry and identified beta-Klotho (KLB) as a locus associated with alcohol consumption (rs11940694; P = 9.2 x 10(-12)). PMID:27911795
A high expression level of KLbeta, but not KLalpha, was an independent predictive factor of short progression free survival for non-muscle invasive bladder cancer PMID:27573985
Our results suggest that KLbeta plays important roles in tumor invasion and progression, and its concentration may be a valuable urinebased marker for the detection of bladder cancer. PMID:27573985
obesity appears as the predominant determinant of the abnormalities in FGF21 and FGF19 levels. Opposite changes in beta-Klotho expression in fat and liver indicate potential tissue-specific alterations in the responsiveness to endocrine FGFs in obesity PMID:24813368
ATF4 signaling pathway is essential for mediating the effect of ER stress on beta-klotho expression. PMID:25727012
Variants in genes involved in feedback regulation of bile acid synthesis (KLB, P=0.06 and FGFR4, P=0.09) were potentially associated with the irritable bowel syndrome-diarrhea subgroup with elevated serum C4. PMID:25070056
In-depth DNA sequencing identified additional genetic coding and noncoding variants in KLB that are associated with fecal bile acids excretion or colonic transit in Irritable bowel syndrome-diarrhea. PMID:24200957
betaKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3beta/cyclin D1 signaling pathway. PMID:23383245
KLB and FGFR1 form a 1:1 heterocomplex independent of the galectin lattice that transitions to a 1:2 complex upon the addition of FGF21. PMID:22523080
KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4 downstream signaling. PMID:22439738
Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PMID:22442730
Deletion of the D1 and the D1-D2 linker (the D1/linker region) from FGFR1c led to beta-Klotho-independent receptor activation by FGF21, suggesting that there may be a direct interaction between FGF21 and the D1/linker region-deficient FGFR1c. PMID:22248288
Polymorphism KLB rs4975017 may influence the colonic transit response to colesevelam in female patients with irritable bowel syndrome with diarrhea. PMID:22271411
Data suggest that KLB is an important regulator in the immortalization of HCECs by facilitating FGF19 growth factor signaling. PMID:22020932
Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho. PMID:21653700
A functional KLB gene variant mediating protein stability associates with colonic transit in irritable bowel syndrome with diarrhea. This association is modulated by 2 genetic variants in FGFR4. PMID:21396369
Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. PMID:20657013
The down-regulation of the renal klotho gene could increase renal damage induced by angiotensin II, while klotho gene induction could have therapeutic possibilities in treating angiotensin II-induced kidney damage. PMID:16358222
Liver-specific activities of FGF19 require Klotho beta. PMID:17627937
a functional FGF19 receptor may consist of FGF receptor (FGFR) and heparan sulfate complexed with either alphaKlotho or betaKlotho PMID:17711860
High expression of Klotho is associated with ovarian disease progression PMID:18259951
Both FGF23 and FGF21 require intact alpha or betaKlotho for signaling, respectively, whereas FGF19 can signal through a Klotho chimera consisting of the N terminus of alphaKlotho and the C terminus of betaKlotho. PMID:18829467
These data demonstrate that the C-terminus of FGF21 is critical for binding to beta-Klotho and the N-terminus is critical for fibroblast growth factor receptor (FGFR) activation. PMID:19059246